Showing 271-280 of 3459 results for "".
Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iScientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, ReA Broad View of the Current Literature
https://practicaldermatology.com/conferences/maui-derm-2024/a-broad-view-of-the-current-literature/20263/Resident Of Distinction Award-winner Jason Klein, MD, PhD, a dermatology resident at the UT Southwestern Medical Center, talks about some of the latest developments in dermatology literature highlighted in review presentations at Maui Derm 2024, including an elegant synopsis of current options for tConsiderations for the Use of Biologics in Children with Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37152/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains the most important factors to understand when prescribing biologics for pediatric atopicAdvances in Wound Care
https://practicaldermatology.com/conferences/maui-derm-2022/maui-derm-2022-video/20040/Robert S. Kirsner, MD, PhD discusses the latest in wound healing science and resulting changes in how leading wound care experts are approaching patient care. From innovative products to greater understanding of the science, there are many options to help patients heal.SARS-CoV-2 and the Skin: Inside the COVID-19 Dermatology Registry
https://practicaldermatology.com/conferences/aad-2021/sars-cov-2-and-the-skin-inside-the-covid-19-dermatology-registry/19921/From COVID Toes to COVID Arms, dermatologic manifestations of SARS-CoV-2 infection and COVID-19 vaccination abound. Esther Freeman, MD, PhD, Director of the COVID-19 Dermatology Registry provides an overview of findings and shares information about the relatively new vaccine registry.Improving Patient Outcomes
https://practicaldermatology.com/topics/practice-management/improving-patient-outcomes/19102/Steven Feldman, MD, PhD, Professor of Dermatology at Wake Forest University in Winston-Salem, NC, discusses typical patterns of how patients use their medications and identifies strategies for improving adherence and building trust with patients. DermTube's coverage of the AAD's 2014 Summer MeetingAnti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.Connective Tissue Disorders Update 2025: Dr. Vleugels
https://reachmd.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.Dermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her work